Advanced maternal grandmother age and maternal age as risk factors for down syndrome in a group of Jordanian families

To study whether advanced maternal age and maternal grandmother age are associated with increased risk of Down syndrome siblings in a group of Jordanian families. This study was conducted on 127 confirmed Down syndrome cases with the age range of 18 weeks gestation to 15 years old, which were referred between the period of 2005-2008 for cytogenetic analysis at the Cytogentics section, Princess Iman Research and Laboratory Sciences Center/King Hussein Medical Center. Maternal and grandmaternal mother ages were obtained directly from the study group when the samples were collected from siblings. The maternal age ranged between 19-45 years while the maternal grandmother's age ranged between 15-49 years. One hundred healthy families were randomly recruited from the hospital staff as a control group. Logistic regression was used for statistical analysis. One hundred seventeen down syndrome cases had free trisomy 21,7 with translocation, 2 mosaic and one with double aneuploidy [47,XXY, +21]. Fifteen cases were diagnosed prenatally while 112 were diagnosed postnatally. The effect of maternal age and maternal grandmother age were found to be significant using logistic regression statistics [P = 0.001; OR= 2.816; 95% CI, 1.48-5.33] for the mother's age and [P = 0.001; OR= 2.902; 95%CI, 1.521-5.53] for the grandmother's age. Advanced maternal and maternal grandmother ages are risk factors for Down syndrome. More studies and investigations are needed for better understanding of the biological factors responsible for the proper meiotic segregation of germ cells during the fetal development of the embryo in advanced maternal and grandmother's age

Hemophilia in Jordan: study of inhibitors and viral status

This work aims at studying inhibitors to factor VIII:C, factor IX: C in Jordanian patients with Hemophilia A and B and the prevalence of hepatitis B, C, HIV viruses in these patients. A total of99 male patients were included in the study. Of these, 83 [83.8%] are hemophilia A and 16 [16.2%] are hemophilia B. All were investigated for inhibitor development by Bethesda assay. Inhibitors for factor VIII:C were additionally test by an ELISA technique. Each Patient's serum was tested by ELISA for the presence of antibodies against hepatitis A, B, and C viruses as well as against HIV I and II. Those found positive for hepatitis C antibodies were tested by PCR for hepatitis C viral RNA. None of the hemophilia B patients were found to have inhibitors. Eight patients [9.6%] of hemophilia A were found to have inhibitors. The prevalence of antibodies for hepatitis C was 25.25%, for hepatitis B 0% and for HIV 1%. Of those who were HCV antibody positive, 13 [52%] were positive for HCV-RNA by PCR. It is concluded that inhibitor development in Jordanian hemophilia A patients is similar to that described in western countries. Regular monitoring of these inhibitors should be an essential part of the routine care and follow-up of hemophilia A patients. The high prevalence of HCV indicates the need for more rigorous hepatitis C screening in local blood to render it safer than it is